Area of research
Molecular Biology · Oncology
Research interest
Research focused on Cancer research and KRAS, with related work in Transactivation, Autophagy, Prostate cancer. Notable publications include 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma', 'Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer', and 'Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13'.
Targeting PIKfyve-driven lipid metabolism in pancreatic cancer
Discovery of HZS60 as a Novel Brain Penetrant NMDAR/TRPM4 Interaction Interface Inhibitor with Improved Activity and Pharmacokinetic Properties for the Treatment of Cerebral Ischemia
Discovery of <b>YJZ5118</b>: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
Discovery of LLC0424 as a Potent and Selective <i>in Vivo</i> NSD2 PROTAC Degrader
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader
Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Construction of Active Protein Materials: Manipulation on Morphology of Salmon Calcitonin Assemblies with Enhanced Bone Regeneration Effect
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer
Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein–Protein Interaction
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma